title: The role of "closed abdomen" hyperthermic intraperitoneal chemotherapy (HIPEC) in the palliative treatment of neoplastic ascites from peritoneal carcinomatosis: report of a single-center experience.
abstract: The purpose of this study was to review the results of a single-center experience in the management of "closed abdomen" hyperthermic intraperitoneal chemotherapy (HIPEC) using a sophisticated technical device (EXIPER®) in the palliative setting of neoplastic ascites from peritoneal carcinomatosis in patients with advanced cancer of different primary sites.
  
  
  
  The study was an open, prospective, single-center, non-randomized study conducted at the Department of Medical Oncology 1, University of Cagliari, Italy, from May 2006 to October 2012. Fifteen patients with peritoneal carcinomatosis were treated with HIPEC: 5 males and 10 females (age range 51-82, median 62 years), for a total of 30 procedures (5 patients were treated more than once). Malignant ascites were from ovarian, uterine cervical, colorectal, gastric, malignant pleural mesothelioma, and unknown primary cancer. Main endpoints were increase of free interval between two consecutive procedures, progressive reduction of ascites volumes and improvement of quality of life assessed with ECOG performance status and EORTC QLQ-C30 questionnaire, and improvement of immunologic function.
  
  
  
  Twelve patients were completely evaluable while three patients were "lost" to follow-up. The treatment was well tolerated. The mean free interval between two consecutive drainages increased from 11.2 to 39.5 days. The mean ascites volume drained decreased from 7.8 to 1.8 l. ECOG PS improved in the majority of patients and EORTC QLQ-C30 scores in all patients as well as immunologic function. In September 2015, only one patient was still alive.
  
  
  
  Our study shows that good results may be achieved in terms of symptom palliation and improvement of quality of life in very advanced cancer patients with MA from PC. The treatment was generally well tolerated considering the limited treatment options available for these patients.
authors.affiliation: Department of Medical Oncology, University of Cagliari, Cagliari, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Orgiano
authors.affiliation: Endocrinology Unit, University of Cagliari, Cagliari, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Pani
authors.affiliation: Department of Medical Oncology, University of Cagliari, Cagliari, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Astara
authors.affiliation: Department of Medical Oncology, University of Cagliari, Cagliari, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Madeddu
authors.affiliation: Radiology Unit, University of Cagliari, Cagliari, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Marini
authors.affiliation: General Surgery, University of Cagliari, Cagliari, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Manca
authors.affiliation: Department of Medical Oncology, University of Cagliari, Cagliari, Italy. mantovan@medicina.unica.it.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Mantovani
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001201:Ascites / Q000188:drug therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care / Q000379:methods*; D010534:Peritoneal Neoplasms / Q000150:complications* / Q000601:surgery / Q000628:therapy; D011446:Prospective Studies; D011788:Quality of Life / Q000523:psychology*
keywords: Hyperthermic intraperitoneal chemotherapy; Malignant ascites; Palliative care setting; Peritoneal carcinomatosis